Fiscal Year Ending December 2026 Third Quarter Financial Summary [IFRS] (Consolidated)

Overview of Results

For Kyowa Kirin Co., Ltd., the third quarter of the fiscal year ending December 2026 recorded revenue of 384,947 million yen, up 10.2% year-over-year, and core operating income increased 46.8%, resulting in a substantial rise in quarterly profit to 51,673 million yen. Currency effects were not negligible; the main drivers were increased overseas revenue and technology income, together with reduced R&D expenses. The full-year forecast remains unchanged at this time. As the company operates with a single pharmaceutical business segment, geographic revenue details are provided in the supplementary materials. Cash increased by 2,411 million yen at the end of the period.

Outlook and Notes

Supplementary explanatory materials and an earnings presentation meeting will be provided. Notes address recent foreign exchange impacts and the application of a revised definition for core metrics, changes in the presentation of financial statements, and revisions to useful lives. The company states that the full-year forecast for the fiscal year ending December 2026 remains unchanged from the time of publication, and highlights significant accounting policy and estimate changes, including the exclusion of Orchard Therapeutics from consolidation.